Westover Capital Advisors LLC Sells 1,560 Shares of Pfizer Inc. (NYSE:PFE)

Westover Capital Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 9,981 shares of the biopharmaceutical company’s stock after selling 1,560 shares during the period. Westover Capital Advisors LLC’s holdings in Pfizer were worth $287,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Trifecta Capital Advisors LLC boosted its stake in shares of Pfizer by 3.7% during the third quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 325 shares in the last quarter. Confluence Wealth Services Inc. grew its holdings in Pfizer by 0.5% during the 3rd quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after acquiring an additional 342 shares during the last quarter. Carr Financial Group Corp grew its holdings in Pfizer by 3.3% during the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 355 shares during the last quarter. Caldwell Sutter Capital Inc. raised its stake in shares of Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock valued at $2,315,000 after acquiring an additional 364 shares during the last quarter. Finally, Lafayette Investments Inc. lifted its holdings in shares of Pfizer by 2.2% during the third quarter. Lafayette Investments Inc. now owns 17,470 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 368 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on PFE. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.00.

Pfizer Stock Up 0.4 %

Pfizer stock traded up $0.11 during midday trading on Friday, reaching $27.81. The stock had a trading volume of 45,367,553 shares, compared to its average volume of 43,148,504. The company has a fifty day moving average price of $26.88 and a two-hundred day moving average price of $28.25. The company has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a PEG ratio of 1.20 and a beta of 0.63. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period in the prior year, the firm earned $1.23 earnings per share. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.28 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.